ANTA Sports to Acquire Major Stake in Puma in €1.5 Billion Deal, Signaling Strategic Revival 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
Zijin Mining Shares Hit Record High on $4 Billion Allied Gold Acquisition 
Samsung Set to Begin HBM4 Production for Nvidia and AMD 
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal 
California Governor Gavin Newsom Launches Review Into Alleged TikTok Content Suppression After U.S. Ownership Deal 
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
SEATTLE, May 16, 2017 -- Nohla Therapeutics Inc. (Nohla), a leading innovator in the development of off-the-shelf universal donor cellular therapies, announced today that Katie Fanning, the company’s president and CEO, will present at the 2017 Life Science Innovation Northwest Conference being held on May 23 and 24 at the Washington State Convention Center in Seattle. Ms. Fanning’s presentation will include an overview of the company’s technology platform, clinical progress, strategic vision, and near term milestones.
Ms. Fanning is scheduled to present on Tuesday, May 23, 2017 at 11:10 a.m. PDT at the Washington State Convention Center in room 618.
Ms. Fanning joined Nohla in February 2017 bringing over 30 years of industry experience holding previous leadership roles in both public and private biopharmaceutical companies. Having most recently served as Chief Operating Officer at VentiRx Pharmaceuticals, Ms. Fanning played an instrumental role in the strategic collaboration between VentiRx and Celgene Corporation.
Life Science Innovation Northwest is the largest annual life science conference in the Pacific Northwest. With more than 500 attendees, the conference offers networking and professional development for researchers and leaders at all stages. This year’s conference will include panel discussions on antimicrobial resistance, precision medicine, data collaboration, philanthrocapitalism, early-stage company investing, digital health, and federal policy. For more information, please visit http://www.lifesciencewa.org/?page=LSINW_17.
About Nohla
Nohla is a clinical stage company dedicated to the development of universal donor cellular therapies for the treatment of patients with blood cancers and other life threatening conditions. The Company is leveraging a platform developed over two decades of preclinical and clinical research, which enables the ex vivo expansion and directed differentiation of stem/progenitor cells resulting in “off-the-shelf” universal donor cellular therapies (which can be used on demand without the need for HLA matching).
Nohla is evaluating the ability of the first of these “off-the-shelf” products to reduce infection and other complications of neutropenia in two lead programs involving multi-center, randomized clinical trials: a Phase 2b study in the setting of cord blood transplant and a global Phase 2 study in the setting of high dose chemotherapy for acute myelogenous leukemia (AML).
For more information, please contact: Jim DeNike Senior Director, Corporate Development & Investor Relations 206.519.5294 [email protected]
